During the past decade, Kansai Medical University Hospital conducted 17 clinical trials. In the 10-year time frame, 17 clinical trials started and 6 clinical trials were completed, i.e. on average, 35.3% percent of trials that started reached the finish line to date. In the past 5 years, 14 clinical trials started and 6 clinical trials were completed. i.e. 42.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Kansai Medical University Hospital" #1 sponsor was "Amgen" with 4 trials, followed by "Hoffmann-La Roche" with 4 trials sponsored, "Daiichi Sankyo, Inc." with 2 trials sponsored, "Pfizer" with 2 trials sponsored and "AbbVie" with 2 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Kansai Medical University Hospital" #1 collaborator was "Arena is a wholly owned subsidiary of Pfizer" with 2 trials as a collaborator, "AstraZeneca" with 2 trials as a collaborator, "BeiGene" with 1 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 1 trials as a collaborator and "Merck Sharp & Dohme LLC" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Kansai Medical University Hospital" are "Ulcerative Colitis" (3 trials), "Carcinoma, Non-Small-Cell Lung" (2 trials), "Gastric Cancer" (2 trials), "Gastroesophageal Junction Adenocarcinoma" (2 trials) and "Adenocarcinoma" (1 trials). Many other conditions were trialed in "Kansai Medical University Hospital" in a lesser frequency.

Most popular intervention types in "Kansai Medical University Hospital" are "Drug" (17 trials), "Other" (3 trials), "Biological" (1 trials), "Device" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "Etrasimod" (3 trials), "Bemarituzumab" (2 trials), "Faricimab" (2 trials) and "Pembrolizumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Kansai Medical University Hospital" are 17 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Kansai Medical University Hospital". undefined are not yet recruiting, 6 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in Kansai Medical University Hospital, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Kansai Medical University Hospital, 1 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 13 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".